Turnstone Biologics Corp. (NASDAQ: TSBX)
$0.4727
-0.0084 ( -2.15% ) 18.8K
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which areĀ referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Market Data
Open
$0.4727
Previous close
$0.4811
Volume
18.8K
Market cap
$11.23M
Day range
$0.4660 - $0.4850
52 week range
$0.4393 - $5.7500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 02, 2024 |
8-k | 8K-related | 11 | Jun 05, 2024 |
8-k | 8K-related | 12 | May 13, 2024 |
10-q | Quarterly Reports | 72 | May 13, 2024 |
def | Proxies and info statements | 5 | Apr 22, 2024 |
ars | Annual reports | 1 | Apr 22, 2024 |
8-k | 8K-related | 13 | Apr 16, 2024 |
3 | Insider transactions | 2 | Apr 16, 2024 |
4 | Insider transactions | 1 | Apr 16, 2024 |
10-k | Annual reports | 94 | Mar 22, 2024 |